Wallace Capital Management Inc. - REATA PHARMACEUTICALS INC ownership

REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 133 filers reported holding REATA PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is 1.20 and the average weighting 0.5%.

Quarter-by-quarter ownership
Wallace Capital Management Inc. ownership history of REATA PHARMACEUTICALS INC
ValueSharesWeighting
Q2 2023$2,260,963
+230.1%
22,175
+205.7%
0.35%
+287.8%
Q2 2019$685,000
+3.3%
7,255
-6.4%
0.09%
-2.2%
Q1 2019$663,000
+52.4%
7,7550.0%0.09%
+46.0%
Q4 2018$435,000
-31.4%
7,7550.0%0.06%
-22.2%
Q3 2018$634,000
+133.9%
7,755
+0.1%
0.08%
+125.0%
Q2 2018$271,0007,7500.04%
Other shareholders
REATA PHARMACEUTICALS INC shareholders Q4 2018
NameSharesValueWeighting ↓
CPMG Inc 2,896,901$291,457,00032.14%
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE 46,646$4,693,0005.31%
Ikarian Capital, LLC 471,400$47,423,0003.34%
Duquesne Family Office 695,033$69,927,0002.27%
Camber Capital Management LP 685,000$68,918,0002.12%
LBJ Family Wealth Advisors, Ltd. 30,359$3,054,0001.82%
MADDEN SECURITIES Corp 33,127$3,333,0001.80%
Biondo Investment Advisors, LLC 104,120$10,475,0001.80%
Tolleson Wealth Management, Inc. 60,750$6,112,0001.73%
Keel Point, LLC 97,074$9,767,0001.26%
View complete list of REATA PHARMACEUTICALS INC shareholders